vs
Astrana Health, Inc.（ASTH）与EXPONENT INC（EXPO）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是EXPONENT INC的6.5倍（$950.5M vs $147.1M）。EXPONENT INC净利率更高（19.1% vs 0.7%，领先18.4%）。Astrana Health, Inc.同比增速更快（42.9% vs 8.0%）。EXPONENT INC自由现金流更多（$30.0M vs $-6.0M）。过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 9.4%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
Exponent Inc.是美国知名工程与科学咨询企业，汇集科学家、医师、工程师及商业咨询专家，可在90余个技术领域开展研究与分析工作，目前在美国本土设有20个办事处，境外另有5个办事网点。
ASTH vs EXPO — 直观对比
营收规模更大
ASTH
是对方的6.5倍
$147.1M
营收增速更快
ASTH
高出34.9%
8.0%
净利率更高
EXPO
高出18.4%
0.7%
自由现金流更多
EXPO
多$35.9M
$-6.0M
两年增速更快
ASTH
近两年复合增速
9.4%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $147.1M |
| 净利润 | $6.6M | $28.0M |
| 毛利率 | — | — |
| 营业利润率 | 1.9% | 19.7% |
| 净利率 | 0.7% | 19.1% |
| 营收同比 | 42.9% | 8.0% |
| 净利润同比 | 184.4% | 7.7% |
| 每股收益（稀释后） | $0.12 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHEXPO
| Q4 25 | $950.5M | $147.1M | ||
| Q3 25 | $956.0M | $142.0M | ||
| Q2 25 | $654.8M | $145.5M | ||
| Q1 25 | $620.4M | $136.8M | ||
| Q4 24 | $665.2M | — | ||
| Q3 24 | $478.7M | $136.3M | ||
| Q2 24 | $486.3M | $140.5M | ||
| Q1 24 | $404.4M | $144.9M |
净利润ASTHEXPO
| Q4 25 | $6.6M | $28.0M | ||
| Q3 25 | $373.0K | $26.6M | ||
| Q2 25 | $9.4M | $26.6M | ||
| Q1 25 | $6.7M | $23.6M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | $16.1M | $26.0M | ||
| Q2 24 | $19.2M | $29.2M | ||
| Q1 24 | $14.8M | $30.1M |
营业利润率ASTHEXPO
| Q4 25 | 1.9% | 19.7% | ||
| Q3 25 | 2.0% | 12.1% | ||
| Q2 25 | 3.1% | 30.5% | ||
| Q1 25 | 3.3% | 19.9% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.9% | 19.0% | ||
| Q2 24 | 6.2% | 25.4% | ||
| Q1 24 | 7.5% | 21.2% |
净利率ASTHEXPO
| Q4 25 | 0.7% | 19.1% | ||
| Q3 25 | 0.0% | 18.7% | ||
| Q2 25 | 1.4% | 18.3% | ||
| Q1 25 | 1.1% | 17.2% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 3.4% | 19.1% | ||
| Q2 24 | 3.9% | 20.8% | ||
| Q1 24 | 3.7% | 20.8% |
每股收益（稀释后）ASTHEXPO
| Q4 25 | $0.12 | $0.55 | ||
| Q3 25 | $0.01 | $0.52 | ||
| Q2 25 | $0.19 | $0.52 | ||
| Q1 25 | $0.14 | $0.45 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $0.33 | $0.50 | ||
| Q2 24 | $0.40 | $0.57 | ||
| Q1 24 | $0.31 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $207.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $779.3M | $402.9M |
| 总资产 | $2.2B | $761.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTHEXPO
| Q4 25 | $429.5M | $207.4M | ||
| Q3 25 | $463.4M | $231.8M | ||
| Q2 25 | $342.1M | $245.1M | ||
| Q1 25 | $260.9M | $258.9M | ||
| Q4 24 | $290.8M | — | ||
| Q3 24 | $350.3M | $219.7M | ||
| Q2 24 | $327.7M | $203.3M | ||
| Q1 24 | $337.3M | $168.7M |
股东权益ASTHEXPO
| Q4 25 | $779.3M | $402.9M | ||
| Q3 25 | $775.5M | $427.8M | ||
| Q2 25 | $765.5M | $441.4M | ||
| Q1 25 | $745.4M | $421.1M | ||
| Q4 24 | $712.7M | — | ||
| Q3 24 | $704.6M | $410.3M | ||
| Q2 24 | $678.9M | $393.2M | ||
| Q1 24 | $653.5M | $374.3M |
总资产ASTHEXPO
| Q4 25 | $2.2B | $761.4M | ||
| Q3 25 | $2.2B | $759.4M | ||
| Q2 25 | $1.4B | $763.2M | ||
| Q1 25 | $1.3B | $777.3M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | $744.1M | ||
| Q2 24 | $1.3B | $709.2M | ||
| Q1 24 | $1.2B | $629.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $32.7M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $30.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 20.4% |
| 资本支出强度资本支出/营收 | 0.3% | 1.8% |
| 现金转化率经营现金流/净利润 | -0.44× | 1.16× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $122.9M |
8季度趋势，按日历期对齐
经营现金流ASTHEXPO
| Q4 25 | $-2.9M | $32.7M | ||
| Q3 25 | $10.0M | $36.2M | ||
| Q2 25 | $90.9M | $7.3M | ||
| Q1 25 | $16.6M | $56.1M | ||
| Q4 24 | $-10.9M | — | ||
| Q3 24 | $34.0M | $29.7M | ||
| Q2 24 | $23.2M | $48.3M | ||
| Q1 24 | $6.0M | $10.4M |
自由现金流ASTHEXPO
| Q4 25 | $-6.0M | $30.0M | ||
| Q3 25 | $7.4M | $33.9M | ||
| Q2 25 | $89.5M | $5.5M | ||
| Q1 25 | $13.6M | $53.5M | ||
| Q4 24 | $-13.5M | — | ||
| Q3 24 | $31.7M | $28.0M | ||
| Q2 24 | $20.4M | $47.2M | ||
| Q1 24 | $5.6M | $8.9M |
自由现金流率ASTHEXPO
| Q4 25 | -0.6% | 20.4% | ||
| Q3 25 | 0.8% | 23.9% | ||
| Q2 25 | 13.7% | 3.8% | ||
| Q1 25 | 2.2% | 39.1% | ||
| Q4 24 | -2.0% | — | ||
| Q3 24 | 6.6% | 20.5% | ||
| Q2 24 | 4.2% | 33.6% | ||
| Q1 24 | 1.4% | 6.2% |
资本支出强度ASTHEXPO
| Q4 25 | 0.3% | 1.8% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 0.2% | 1.2% | ||
| Q1 25 | 0.5% | 1.9% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.6% | 0.8% | ||
| Q1 24 | 0.1% | 1.0% |
现金转化率ASTHEXPO
| Q4 25 | -0.44× | 1.16× | ||
| Q3 25 | 26.69× | 1.36× | ||
| Q2 25 | 9.65× | 0.27× | ||
| Q1 25 | 2.48× | 2.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | 1.14× | ||
| Q2 24 | 1.21× | 1.65× | ||
| Q1 24 | 0.40× | 0.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
EXPO
| Engineering And Other Scientific | $124.0M | 84% |
| Environmental And Health | $23.1M | 16% |
